drugset / Trial / NCT07480681
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic profiles, and preliminary efficacy of HLX97 ( KAT6A/B inhibitor) in patients with advanced/metastatic solid tumors.
Timeline
- Start
- 2026-03
- Primary completion
- 2028-03
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX97 | Small molecule | — | Oral |
| Background | Fulvestrant | Small molecule | — | Intramuscular |
Indications
No indication recorded.